Incorporating Immuno-oncology Agents into Solid and Liquid Tumor Treatment Paradigms: Highlights from ASCO 2017 – Expert Discussion

Target Audience

This activity has been designed to meet the educational needs of medical oncology and hematology-oncology physicians and advanced practitioners in community and academic settings treating patients with cancer.

Program Overview

Immunotherapy is now an established treatment approach for patients with cancer across oncology. Immunotherapy agents are a newer type of anticancer drug, and the drugs in the largest class, checkpoint inhibitors, block the checkpoint pathways that cancer cells use to shut down the patient’s immune system. Checkpoint inhibitors are associated with more durable clinical responses compared to both small molecule targeted therapy and conventional chemotherapy (CT). Because checkpoint inhibitors have unique mechanisms of action, they also produce immune-related adverse events and response patterns that are markedly distinct from targeted agents or conventional CT. The 5 currently available immunotherapy agents have 18 indications across multiple cancer types. Checkpoint inhibitors demonstrate the potential to change current cancer treatment paradigms.

In this interactive CE activity, a leading medical oncologist discusses highlights of several key presentations from the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting on the use of checkpoint inhibitors in several cancer types. Topics include questions on appropriate clinical setting for immunotherapy (eg, refractory cancer), dose, combination therapy, treatment beyond progression, and side-effect profile for patients.


Goal

The goal of this program is to help medical oncology and hematology-oncology physicians and advanced practitioners (NP/PA/PharmD), in community and academic settings, to integrate checkpoint inhibitors into cancer treatment regimens and understand their unique safety and response profiles.

Educational Objectives

Upon completion of this activity, participants will be better able to do the following:

  1. SUMMARIZE available and investigational immune-oncology therapies and their potential use in clinical practice.
  2. INTEGRATE already and late-stage immune-oncology agents into cancer treatment regimens.
  3. IDENTIFY the unique irAEs and response patterns of IO therapies and their implications for cancer treatment.

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty Relationship Identified With:
Jeffrey Clarke, MD

Consultant/Advisor: Inivata Ltd

Grant/Research Support: AbbVie Inc, Adaptimmune Therapeutics plc, Genentech, Inc, Eli Lilly and Company, MedPacto Inc.

Non-faculty

Sandy Breslow; Alison Kemp; Bernard M. Abrams, MD; Daniel Guinee; Mary Gabb, MS; and, Lisa Mangione hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months.

Financial Support

This activity has been supported by independent educational grants from Bristol-Myers Squibb Company and Merck & Co Inc.

Provider Information

Jointly provided by the Elsevier Office of Continuing Medical Education ASiM CE LLC.

CME CREDIT (PHYSICIANS)

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and ASiM CE LLC, The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME INQUIRIES/SPECIAL NEEDS

For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, ASiM CE LLC, and Bristol-Myers Squibb Company and Merck & Co Inc do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Physicians who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME Certificate.
  6. All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.

Release date: December 15, 2017
Expiration date: December 14, 2018